{"nctId":"NCT00537680","briefTitle":"Study to Assess the Efficacy, Safety and Tolerability of Idebenone in the Treatment of Friedreich's Ataxia","startDateStruct":{"date":"2007-12"},"conditions":["Friedreich's Ataxia"],"count":70,"armGroups":[{"label":"Arm 1 - 900 mg/day Idebenone","type":"EXPERIMENTAL","interventionNames":["Drug: Idebenone"]},{"label":"Arm 2 - up to 2250 mg/day Idebenone","type":"EXPERIMENTAL","interventionNames":["Drug: Idebenone"]},{"label":"Arm 3 - Placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Idebenone","otherNames":[]},{"name":"Idebenone","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Documented diagnosis of Friedreich's Ataxia (FRDA) with confirmed FRDA mutations\n* Patients 8 - 17 years of age at baseline\n* Patients with a body weight greater than 25 kg/55 lbs at baseline\n* Patients able to walk at least 10 meters without accompanying person (ICARS Walking Capacities score â‰¤6) at screening and baseline\n* Patients who in the opinion of the investigator are able to comply with the requirements of the study, including swallowing the study medication\n* Negative urine pregnancy test at screening and baseline (female patients of childbearing potential)\n\nExclusion criteria:\n\n* Treatment with idebenone, Coenzyme Q10 or vitamin E (if taken at a dose 5 times above the daily requirement) within the past month\n* Patients with International Cooperative Ataxia Rating Scale (ICARS) score of greater than 54 or less than 10 at screening\n* Pregnancy and/or breast-feeding\n* Clinically significant abnormalities of clinical hematology or biochemistry including, but not limited to, elevations greater than 1.5 times the upper limit of normal of Aspartate Aminotransferase (AST; also known as GOT), Alanine Aminotransferase (ALT; also known as GPT) or creatinine\n* History of abuse of drugs or alcohol\n* Participation in the previous (Phase II) study of idebenone at the National Institutes of Health (NIH)\n* Participation in a trial of another investigational drug within the last 3 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"8 Years","maximumAge":"17 Years","stdAges":["CHILD"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in the International Cooperative Ataxia Rating Scale (ICARS) From Baseline Assessment to Week 24","description":"International Cooperative Ataxia Rating Scale (ICARS):\n\nICARS consists of a one-hundred-point semi-quantitative scale based upon 19 simple testing manoeuvres compartmentalized into postural and stance disorders, limb ataxia, dysarthria and oculomotor disorders and has been previously used in this patient population with good inter-rater reliability.\n\nMinimum score: 0, maximum score 100, higher score indicates greater impairment\n\nCalculation details: ICARS score at week 24 minus ICARS score baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-2.5","spread":"6.3"},{"groupId":"OG001","value":"-2.4","spread":"4.8"},{"groupId":"OG002","value":"-1.3","spread":"4.4"}]}]}]},{"type":"SECONDARY","title":"Change in Friedreich's Ataxia Rating Scale (FARS) Scores From Baseline to Week 24","description":"To compare the efficacy of 6 months' treatment with 2 different doses of idebenone with that of placebo on neurological function as assessed by the Friedreich's Ataxia Rating Scale (FARS)\n\nFARS consists of a 25 manoeuvre exam along with 4 quantitative performance measures. The neurological exam covers bulbar function, upper limb coordination, lower limb coordination, peripheral nervous system function, deep tendon reflexes, stability and gait. The use of FARS has been recently validated as a sensitive scale for this population.\n\nThe FARS exam scores can be added to make a total score ranging from 0 to 159. A higher score indicates a greater level of disability.\n\nCalculation details FARS score at week 24 minus FARS score baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.6","spread":"6.52"},{"groupId":"OG001","value":"-1.2","spread":"4.53"},{"groupId":"OG002","value":"0.6","spread":"5.91"}]}]}]},{"type":"SECONDARY","title":"Activities of Daily Living (ADL) of Friedreich's Ataxia Rating Scale (FARS), Change in ADL (Total Score ) From Baseline to Week 24","description":"To compare the efficacy of 6 months' treatment with 2 different doses of idebenone with that of placebo on Activities of Daily Living (ADL) assessed by the ADL scale of the Friedreich's Ataxia Rating Scale (FARS)\n\nscore 0 to 36, higher score indicates greater impairment","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"2.45"},{"groupId":"OG001","value":"0.6","spread":"3.13"},{"groupId":"OG002","value":"1.0","spread":"2.97"}]}]}]},{"type":"SECONDARY","title":"Change in the International Cooperative Ataxia Rating Scale (ICARS) From Baseline Assessment to Week 12","description":"To compare the efficacy of 3 months' treatment with 2 different doses of idebenone with that of placebo on neurological impairment as assessed by the International Cooperative Ataxia Rating Scale (ICARS)\n\nInternational Cooperative Ataxia Rating Scale (ICARS):\n\nICARS consists of a one-hundred-point semi-quantitative scale based upon 19 simple testing manoeuvres compartmentalized into postural and stance disorders, limb ataxia, dysarthria and oculomotor disorders and has been previously used in this patient population with good inter-rater reliability.\n\nMinimum score: 0, maximum score 100, higher score indicates greater impairment\n\nCalculation details: ICARS score at week 12 minus ICARS score baseline","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.5","spread":"5.35"},{"groupId":"OG001","value":"-1.6","spread":"5.53"},{"groupId":"OG002","value":"-3.0","spread":"3.52"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline to Week 24 in the Relative Wall Thickness (RWT) of the Left Ventricle","description":"To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.032","spread":"0.096"},{"groupId":"OG001","value":"0.007","spread":"0.071"},{"groupId":"OG002","value":"0.010","spread":"0.097"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 24 in the Relative Wall Thickness (RWT) of the Left Ventricle","description":"To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.32","spread":"15.300"},{"groupId":"OG001","value":"1.53","spread":"12.560"},{"groupId":"OG002","value":"2.65","spread":"17.135"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline to Week 24 in Left Ventricular Mass Index (LVMI)","description":"To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-3.06","spread":"6.23"},{"groupId":"OG001","value":"-2.56","spread":"4.27"},{"groupId":"OG002","value":"-1.26","spread":"6.47"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 24 in Left Ventricular Mass Index","description":"To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-4.5","spread":"11.302"},{"groupId":"OG001","value":"-4.9","spread":"8.713"},{"groupId":"OG002","value":"-1.7","spread":"12.382"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline to Week 24 in the Thickness of the Posterior Wall (PW) of the Left Ventricle","description":"To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.018","spread":"0.137"},{"groupId":"OG001","value":"-0.004","spread":"0.112"},{"groupId":"OG002","value":"-0.038","spread":"0.153"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 24 in the Thickness of the Posterior Wall (PW) of the Left Ventricle","description":"To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.075","spread":"13.379"},{"groupId":"OG001","value":"0.12","spread":"12.549"},{"groupId":"OG002","value":"-3.04","spread":"14.651"}]}]}]},{"type":"SECONDARY","title":"Absolute Change From Baseline to Week 24 in the Thickness of the Interventricular Septum (IVS)","description":"To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-0.014","spread":"0.1983"},{"groupId":"OG001","value":"0.021","spread":"0.1474"},{"groupId":"OG002","value":"0.063","spread":"0.1952"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline to Week 24 in the Thickness of the Interventricular Septum (IVS)","description":"To compare the effects of idebenone on cardiac anatomy and function in patients with Friedreich's ataxia (FRDA) as assessed by echocardiography","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.3","spread":"18.160"},{"groupId":"OG001","value":"2.6","spread":"13.084"},{"groupId":"OG002","value":"7.8","spread":"19.480"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":22},"commonTop":["Infections","Nervous system disorders","Gastrointestinal disorders","General disorders","Musculoskeletal & connective tissue disorders"]}}}